|Bid||0.118 x 0|
|Ask||0.120 x 0|
|Day's Range||0.117 - 0.121|
|52 Week Range||0.117 - 0.230|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 22, 2007|
|1y Target Est||N/A|
Uni-Bio Science Group (HKG:690) has had a rough three months with its share price down 6.1%. It is possible that the...
HONG KONG / ACCESSWIRE / March 31, 2020 / A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2019 (the "Year"), as well as its comparatively figures for the year ended 31 December 2018 ("2018"). During the Year, the Group has recorded a spectrum of accomplishments both in terms of marketed products, and consolidation of the Group's assets. The Group has initiated two new research projects in November 2019 on this product line, aiming to expand its application to new patient groups.
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better...